Last reviewed · How we verify
Subcutaneous Abatacept
At a glance
| Generic name | Subcutaneous Abatacept |
|---|---|
| Sponsor | Orrin M Troum, M.D. and Medical Associates |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (PHASE1)
- Study of COYA 302 for the Treatment of ALS (PHASE2)
- Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes (PHASE2)
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Abatacept for the Treatment of Giant Cell Arteritis (PHASE3)
- Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease (PHASE2)
- Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis (PHASE3)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subcutaneous Abatacept CI brief — competitive landscape report
- Subcutaneous Abatacept updates RSS · CI watch RSS
- Orrin M Troum, M.D. and Medical Associates portfolio CI